Clinical Trials Logo

Dry Eye clinical trials

View clinical trials related to Dry Eye.

Filter by:

NCT ID: NCT03226444 Completed - Dry Eye Clinical Trials

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Start date: June 30, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome

NCT ID: NCT03211351 Completed - Dry Eye Clinical Trials

Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

With the potential to address evaporative dry eye, Liposic and Tears Naturale Forte have been developed in which phospholipid liposomes are delivered to the tear film via the surface of the closed eyelid. This study compare the effects of Liposic and Tears Naturale Forte application on the lipid and stability of the tear film in dry eye patients

NCT ID: NCT03208673 Completed - Dry Eye Clinical Trials

Optive Brand For Day And Night Dry Eye Management

Start date: July 3, 2017
Phase: N/A
Study type: Interventional

This is an open label study of Optive eyedrops and gel combination for day and night dry eye management

NCT ID: NCT03204903 Recruiting - Dry Eye Clinical Trials

Laser Acupuncture for Dry Eye

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Subjects with dry eye are enrolled at two ophthalmic centers and randomly assigned to a laser acupuncture group and control group under conventional treatment with artificial tears. The effects of laser acupuncture therapy for patients with dry eye are investigated.

NCT ID: NCT03194698 Completed - Dry Eye Clinical Trials

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

Start date: August 17, 2017
Phase: N/A
Study type: Interventional

Dry eye disease (DED) is a common condition that causes ocular discomfort and reduces visual acuity. The two categories of DED are evaporative dry eye and aqueous deficient dry eye. Both conditions can involve pathology of the meibomian glands, lacrimal glands, lids, tear film and surface cells. Meibomian gland dysfunction (MGD) is the leading cause of evaporative dry eye and contributes to aqueous deficient dry eye. The goal of MGD therapy is to provide long term improvement of symptoms for patients by improving the quality of meibum, increasing meibum flow, improving tear film stability and decreasing inflammation. Commonly used therapies include preservative free drops, omega-3 fatty acid supplementation, topical cyclosporine, serum tears, topical azithromycin, oral doxycycline, moisture chambers, intraductal probing, lib margin exfoliation, automated thermal pulsation, warm compresses, among other. Despite this variety of symptoms, patients often do not experience complete or long term relief of symptoms. Forced meibomian gland expression (MGX) has been shown to be an effective method of rehabilitating meibomian glands and improving dry eye symptoms. The eyelid margins are forcefully compressed to express gland contents. Research has shown improvement in patient symptoms with the use of MGX. Intense pulsed light (IPL) have been used in dermatology to treat various conditions. Patients with DED who have tried other therapies and found no relief, often resort to IPL as a last resort. Research has shown IPL alone may be effective in improving patient symptoms. In addition, such studies have failed to show significant adverse events with the use of IPL. Here, we propose a prospective, randomized, case controlled clinical pilot study to examine the efficacy for both subjective and objective measures. 20 patients with DED will be recruited and will be randomly assigned to one of two groups: MGX alone or MGX with IPL. Objective measures will include tear cytokine levels, impression cytology, meibography, tear osmolarity and others. Subjective measures will include quality of life screening tools. We hypothesize that the use of MGX with IPL will lead to greater improvement in subjective dry eye symptoms and objective measures. Given the lack of adverse effects reported in the literature, we do not anticipate adverse effects in our study. Rochester staff Drs. Faustch and Bourne are providing clinical research advice but have no contact with subjects or biospecimens.

NCT ID: NCT03183089 Completed - Dry Eye Clinical Trials

Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye

Start date: December 3, 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the efficacy of Rohto Dry-Aid® in comparison to Systane® Ultra on visual function and tear film stability in patients diagnosed with Dry Eye.

NCT ID: NCT03180047 Completed - Dry Eye Clinical Trials

Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

Start date: March 31, 2017
Phase: N/A
Study type: Interventional

This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.

NCT ID: NCT03141931 Completed - Dry Eye Clinical Trials

The Effects of Dietary Supplementation With Omega-3 Fatty Acids on Symptoms of Dry Eye

Start date: August 21, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare ocular symptoms and signs when the test nutraceutical formulation (combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids) is consumed daily over a 3 month period, with a control capsule that contains polyethylene glycol (PEG), oleic acid and propylene glycol, which are found in many pharmaceutical products and are generally considered to be biologically inert and safe. There is good evidence that the consumption of oily fish has a protective effect against dry eye, and other studies have provided evidence of the beneficial effect of supplementation with omega-3 essential fatty acids in the treatment of dry eye disease. However, there have been limited well designed clinical trials investigating the potential for nutraceutical dietary supplementation to impact ocular comfort. To date, no controlled, randomised clinical trials have been conducted to evaluate the test nutraceutical formulation. Therefore, the purpose of this study is to conduct a randomized, placebo-controlled, double-masked study to investigate the effects of dietary supplementation with a combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids on ocular comfort including signs and symptoms of dry eye.

NCT ID: NCT03116776 Recruiting - Dry Eye Clinical Trials

Walnut Shell Glasses Moxibustion for Dry Eye Syndrome

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

This trial is designed to evaluate the efficacy of walnut shell glasses moxibustion for dry eye syndrome compared with sodium hyaluronate eye drops.

NCT ID: NCT03097614 Completed - Dry Eye Clinical Trials

Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

Start date: March 31, 2017
Phase: N/A
Study type: Interventional

This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.